Key result
High-dose cyclophosphamide linked to ~8-fold higher cardiotoxicity risk during bone marrow grafting.
Why the study?
Definitive risk factors for cyclophosphamide cardiotoxicity in bone marrow transplantation patients have not been described, particularly regarding dose per body surface area.
Cohort (n=80)
No
Answers are grounded in this paper and cite their sources.
Higher CYA doses per BSA were associated with cardiotoxicity; supports BSA-based dosing but leaves practice change open pending prospective data.
Patients who undergo bone marrow transplantation are generally immunosuppressed with a dose of cyclophosphamide (CYA) which is usually calculated based on the patient's weight. At these high doses of CYA, serious cardiotoxicity may occur, but definitive risk factors for the development of such cardiotoxicity have not been described. Since chemotherapeutic agent toxicity generally correlates with dose per body surface area, we retrospectively calculated the dose of CYA in patients transplanted at our institution to determine whether the incidence of CYA cardiotoxicity correlated with the dose per body surface area. Eighty patients who were to receive CYA 50 mg/kg/d for four days as preparation for marrow grafting underwent a total of 84 transplants for aplastic anemia, Wiskott-Aldrich syndrome, or severe combined immunodeficiency syndrome. Fourteen of 84 (17%) patients had symptoms and signs consistent with CYA cardiotoxicity within ten days of receiving 1 to 4 doses of CYA. Six of the 14 patients died with congestive heart failure. The dose of CYA per body surface area was calculated for all patients and the patients were divided into two groups based on daily CYA dose: Group 1, CYA less than or equal to 1.55 g/m2/d; Group 2, CYA greater than 1.55 g/m2/d. Cardiotoxicity that was thought to be related to CYA occurred in 1/32 (3%) of patients in Group 1 and in 13/52 (25%) patients in Group 2 (P less than 0.025). Congestive heart failure caused or contributed to death in 0/32 patients in Group 1 v 6/52 (12%) of patients in Group 2 (P less than 0.25). There was no difference in the rate of engraftment of evaluable patients in the two groups (P greater than 0.5). We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight. This study reaffirms the principle that drug toxicity correlates with dose per body surface area.
No takes yet. Share an insight, caveat, or question.
Goldberg et al. (1986) conducted a cohort in Aplastic anemia, Wiskott-Aldrich syndrome, or severe combined immunodeficiency syndrome undergoing bone marrow transplantation (n=80). Cyclophosphamide dose > 1.55 g/m2/d vs. Cyclophosphamide dose <= 1.55 g/m2/d was evaluated on Cyclophosphamide cardiotoxicity (p=<0.025). Cyclophosphamide doses >1.55 g/m2/d were associated with a significantly higher incidence of cardiotoxicity (25%) compared to doses ≤1.55 g/m2/d (3%; P<0.025) during bone marrow grafting.
Synapse has enriched 10 related papers. Consider them for comparative context: